|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MGAT2 |
Gene summary for MGAT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MGAT2 | Gene ID | 4247 |
| Gene name | alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase | |
| Gene Alias | CDG2A | |
| Cytomap | 14q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q10469 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4247 | MGAT2 | LZE4T | Human | Esophagus | ESCC | 4.72e-07 | 9.92e-02 | 0.0811 |
| 4247 | MGAT2 | LZE20T | Human | Esophagus | ESCC | 3.87e-05 | 1.67e-01 | 0.0662 |
| 4247 | MGAT2 | LZE22T | Human | Esophagus | ESCC | 1.35e-03 | 3.32e-01 | 0.068 |
| 4247 | MGAT2 | LZE24T | Human | Esophagus | ESCC | 5.70e-13 | 3.55e-01 | 0.0596 |
| 4247 | MGAT2 | LZE21T | Human | Esophagus | ESCC | 2.98e-02 | 2.16e-01 | 0.0655 |
| 4247 | MGAT2 | P1T-E | Human | Esophagus | ESCC | 1.20e-04 | 2.82e-01 | 0.0875 |
| 4247 | MGAT2 | P2T-E | Human | Esophagus | ESCC | 3.06e-17 | 2.46e-01 | 0.1177 |
| 4247 | MGAT2 | P4T-E | Human | Esophagus | ESCC | 1.85e-23 | 4.08e-01 | 0.1323 |
| 4247 | MGAT2 | P5T-E | Human | Esophagus | ESCC | 2.43e-27 | 6.48e-01 | 0.1327 |
| 4247 | MGAT2 | P8T-E | Human | Esophagus | ESCC | 1.16e-14 | 2.65e-01 | 0.0889 |
| 4247 | MGAT2 | P9T-E | Human | Esophagus | ESCC | 3.45e-12 | 1.88e-01 | 0.1131 |
| 4247 | MGAT2 | P10T-E | Human | Esophagus | ESCC | 2.56e-17 | 3.28e-01 | 0.116 |
| 4247 | MGAT2 | P11T-E | Human | Esophagus | ESCC | 8.65e-11 | 4.43e-01 | 0.1426 |
| 4247 | MGAT2 | P12T-E | Human | Esophagus | ESCC | 4.57e-16 | 3.70e-01 | 0.1122 |
| 4247 | MGAT2 | P15T-E | Human | Esophagus | ESCC | 1.17e-24 | 5.79e-01 | 0.1149 |
| 4247 | MGAT2 | P16T-E | Human | Esophagus | ESCC | 3.09e-08 | 1.75e-01 | 0.1153 |
| 4247 | MGAT2 | P17T-E | Human | Esophagus | ESCC | 1.07e-08 | 3.18e-01 | 0.1278 |
| 4247 | MGAT2 | P19T-E | Human | Esophagus | ESCC | 3.06e-09 | 4.62e-01 | 0.1662 |
| 4247 | MGAT2 | P20T-E | Human | Esophagus | ESCC | 1.16e-10 | 2.24e-01 | 0.1124 |
| 4247 | MGAT2 | P21T-E | Human | Esophagus | ESCC | 8.66e-17 | 2.88e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00181969 | Esophagus | ESCC | peptidyl-asparagine modification | 22/8552 | 24/18723 | 2.82e-06 | 3.21e-05 | 22 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00182799 | Esophagus | ESCC | protein N-linked glycosylation via asparagine | 21/8552 | 23/18723 | 5.69e-06 | 5.90e-05 | 21 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00190826 | Esophagus | ESCC | viral protein processing | 24/8552 | 29/18723 | 4.50e-05 | 3.55e-04 | 24 |
| GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
| GO:001603212 | Liver | Cirrhotic | viral process | 203/4634 | 415/18723 | 5.40e-27 | 3.76e-24 | 203 |
| GO:001908011 | Liver | Cirrhotic | viral gene expression | 52/4634 | 94/18723 | 2.19e-10 | 1.08e-08 | 52 |
| GO:00182795 | Liver | Cirrhotic | protein N-linked glycosylation via asparagine | 16/4634 | 23/18723 | 7.54e-06 | 1.15e-04 | 16 |
| GO:00181965 | Liver | Cirrhotic | peptidyl-asparagine modification | 16/4634 | 24/18723 | 1.74e-05 | 2.37e-04 | 16 |
| GO:00064873 | Liver | Cirrhotic | protein N-linked glycosylation | 30/4634 | 65/18723 | 1.40e-04 | 1.36e-03 | 30 |
| GO:00160511 | Liver | Cirrhotic | carbohydrate biosynthetic process | 73/4634 | 202/18723 | 1.91e-04 | 1.77e-03 | 73 |
| GO:00190824 | Liver | Cirrhotic | viral protein processing | 15/4634 | 29/18723 | 1.59e-03 | 1.03e-02 | 15 |
| GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
| hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
| hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
| hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
| hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
| hsa005134 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
| hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
| hsa0051311 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
| hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
| hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
| hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa005135 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
| hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa0051312 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
| hsa0051022 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
| hsa0051321 | Oral cavity | LP | Various types of N-glycan biosynthesis | 22/2418 | 42/8465 | 9.58e-04 | 4.49e-03 | 2.90e-03 | 22 |
| hsa0051032 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
| hsa0051331 | Oral cavity | LP | Various types of N-glycan biosynthesis | 22/2418 | 42/8465 | 9.58e-04 | 4.49e-03 | 2.90e-03 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MGAT2 | SNV | Missense_Mutation | novel | c.844G>C | p.Glu282Gln | p.E282Q | Q10469 | protein_coding | tolerated(0.46) | benign(0.065) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| MGAT2 | SNV | Missense_Mutation | c.725N>T | p.Trp242Leu | p.W242L | Q10469 | protein_coding | deleterious(0.01) | possibly_damaging(0.688) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MGAT2 | insertion | Nonsense_Mutation | novel | c.1171_1172insTGGAATTCTATTTATAAGTAAAA | p.Gln391LeufsTer6 | p.Q391Lfs*6 | Q10469 | protein_coding | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| MGAT2 | SNV | Missense_Mutation | c.581N>C | p.Arg194Thr | p.R194T | Q10469 | protein_coding | deleterious(0.03) | benign(0.102) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| MGAT2 | SNV | Missense_Mutation | c.310N>A | p.Leu104Met | p.L104M | Q10469 | protein_coding | deleterious(0) | possibly_damaging(0.902) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MGAT2 | insertion | In_Frame_Ins | novel | c.1227_1228insTTTTGG | p.Glu409_Thr410insPheTrp | p.E409_T410insFW | Q10469 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MGAT2 | deletion | Frame_Shift_Del | c.341delN | p.Arg116GlyfsTer48 | p.R116Gfs*48 | Q10469 | protein_coding | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| MGAT2 | SNV | Missense_Mutation | c.310C>A | p.Leu104Met | p.L104M | Q10469 | protein_coding | deleterious(0) | possibly_damaging(0.902) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MGAT2 | SNV | Missense_Mutation | novel | c.742C>A | p.Leu248Ile | p.L248I | Q10469 | protein_coding | tolerated(0.12) | possibly_damaging(0.837) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MGAT2 | SNV | Missense_Mutation | novel | c.606N>T | p.Lys202Asn | p.K202N | Q10469 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4247 | MGAT2 | ENZYME | Phenylmethanesulfonamide derivative 1 | |||
| 4247 | MGAT2 | ENZYME | Dihydropyrimidinone derivative 4 | |||
| 4247 | MGAT2 | ENZYME | Bicyclic pyrimidine derivative 1 | |||
| 4247 | MGAT2 | ENZYME | Pyrimidine-4(3H)-one derivative 1 | |||
| 4247 | MGAT2 | ENZYME | N-containing heterocyclic derivative 1 | |||
| 4247 | MGAT2 | ENZYME | Dihydropyrimidinone derivative 3 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |